Evaluating respiratory responses to hyperventilation and mannitol in asthma patients
Sensory-Mechanical Responses to Eucapneic Voluntary Hyperventilation and Mannitol in Individuals With Cough Variant Asthma and Chronic Cough
This study is testing how people with cough variant asthma and those with cough from other causes respond to breathing exercises and a medication to see if it helps us understand their coughing better.
Quick facts
| Phase | Phase 4 |
|---|---|
| Study type | Interventional |
| Enrollment | 30 (estimated) |
| Ages | 18 Years to 65 Years |
| Sex | All |
| Sponsor | Queen's University Academic / other |
| Locations | 1 site (Kingston, Ontario) |
| Trial ID | NCT03105843 on ClinicalTrials.gov |
What this trial studies
This study aims to assess the sensory-mechanical responses of individuals with cough variant asthma (CVA) and those with methacholine-induced cough but normal airway sensitivity to eucapneic voluntary hyperventilation (EVH) and mannitol inhalation. Participants will undergo these challenges, and their responses will be compared to a control group of healthy individuals without asthma or chronic cough. The research seeks to deepen the understanding of the pathophysiological mechanisms underlying cough in these conditions. The study will collect preliminary data to inform future research and treatment strategies.
Who should consider this trial
Good fit: Ideal candidates include individuals aged 18-65 with cough variant asthma or chronic cough with normal airway sensitivity.
Not a fit: Patients with recent exacerbations, significant smoking history, or those unable to perform spirometry may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved understanding and management of cough variant asthma and related conditions.
How similar studies have performed: While the specific combination of EVH and mannitol in this context is novel, similar approaches have shown promise in understanding asthma and cough mechanisms.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Individuals aged 18-65 years of age with CVA and individuals with methacholine-induced cough but normal airway sensitivity. The following definitions will be used: 1. CVA: chronic cough (≥8 weeks) is the sole or predominant symptom and positive methacholine challenge (PC20 ≤ 16 mg/mL) and history of cough responding to specific asthma treatment (such as inhaled steroid or 1 week trial of bronchodilator); 2. Methacholine-induced cough but normal airway sensitivity: chronic cough (≥8 weeks) is the sole or predominant symptom and negative methacholine challenges (PC20 \> 16 mg/mL). * Individuals aged 18-65 years of age with no history of asthma or chronic cough. Exclusion Criteria: * an exacerbation necessitating a change in medication, emergency department visit or hospitalizations within the previous 4 weeks * inability to perform acceptable spirometry * medical contraindications to methacholine challenge testing * smoking history in excess of 10 pack years Note: Previous treatment with inhaled or systemic corticosteroids is not an exclusion criterion; medication use will be recorded and examined in the analysis.
Where this trial is running
Kingston, Ontario
- Kingston Health Sciences Centre — Kingston, Ontario, Canada (Recruiting)
Study contacts
- Principal investigator: M. Diane Lougheed, MD, MSc — Department of Medicine, Queen's University
- Study coordinator: M. Diane Lougheed, MD, MSc
- Email: diane.lougheed@kingstonhsc.ca
- Phone: 613-548-2348
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.